# Thromboxane Receptor Antagonist to Improve Endothelial Function

> **NCT03962855** · PHASE2 · COMPLETED · sponsor: **Jeffrey Rade** · enrollment: 57 (actual)

## Conditions studied

- Cardiovascular Diseases
- Vascular Dilation

## Interventions

- **DRUG:** Ifetroban Sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03962855
- **Lead sponsor:** Jeffrey Rade
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-20
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-11-15
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962855, "Thromboxane Receptor Antagonist to Improve Endothelial Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03962855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*